Arvinas, Pfizer announce VERITAC-2 trial did not reach statistical significance
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade
Key Points Pfizer and Novo Nordisk have underperformed the market over the past year. But both should remain major players in important areas within the pharma industry. Investors could see the two drugmakers' shares beat the market over the next decade. 10 stocks we like better than Pfizer › Pharmaceutical giants Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) have lagged the market over the past year, although Pfizer's poor performance dates back much further. Though these companies have encountered challenges, there are good reasons to be bullish on their long-term prospects. Pfizer could become an even bigger player in the oncology market (the largest therapeutic area in the industry by sales) over the next decade, while Novo Nordisk will be a major player in diabetes and the fast-growing weight management space. Both could produce excellent results along the way. Here's the rundown. 1. Pfizer Pfizer's financial results haven't been great in recent years. To make matters worse, the company will face important patent cliffs by the end of the decade. One of them will be for Eliquis, an anticoagulant that is still one of its best-selling medicines. However, Pfizer has prepared for that eventuality. The company made several acquisitions and licensing deals that significantly boosted its pipeline, especially in oncology. Pfizer spent $43 billion to acquire Seagen, a smaller cancer specialist whose lineup and pipeline were impressive for a company of its size. With the financial and strategic backing of the larger company, it should yield even more key approvals in the field in the coming years. Pfizer also recently made an up-front payment of $1.25 billion to China-based 3SBio for the rights to SSGJ-707, an investigational bispecific antibody, a portion of the oncology market that's gaining traction these days. 3SBio will be eligible for commercial and regulatory milestone payments of up to $4.8 billion, not including royalties. These moves should eventually pay off for Pfizer and strengthen its position in oncology. The drugmaker plans to have eight blockbuster cancer medicines on the market by 2030, up from its current five, while doubling its reach from the current 1 million patients it serves. Of course, Pfizer isn't just a cancer play. The company's extensive pipeline should enable it to launch products in other areas and ultimately get back on track. While its shares have been lagging the market significantly, that could change in the next decade as financial results rebound thanks to its innovative efforts. Pfizer's shares look especially attractive when considering its valuation. Its forward price-to-earnings (P/E) ratio is 8.7, much lower than the healthcare sector's 15.8. From their current levels, Pfizer's shares could go on to generate excellent returns through 2035. 2. Novo Nordisk Novo Nordisk pioneered the market for weight management medicines. However, Eli Lilly seems to have taken the lead in that field, at least for now. Novo Nordisk has faced some clinical setbacks, leading to a poor performance over the trailing-12-month period. Can the company rebound and perform well in the next decade? In my view, it can, and the market may be significantly undervaluing its potential. Its sales of Wegovy, one of the top-selling anti-obesity medications, continue to grow rapidly. Novo Nordisk recently requested approval from the U.S. Food and Drug Administration for oral semaglutide (the active ingredient in Wegovy). That's good for patients who want a non-injected option, and helps counter Lilly's up-and-coming oral GLP-1 medicine, orforglipron. Elsewhere, Novo Nordisk recently started phase 3 studies for amycretin, a next-gen weight loss candidate. Amycretin is being investigated in both oral and subcutaneous formulations, and both are currently in late-stage clinical trials. The company also enhanced its pipeline through licensing deals, including one with United Biotechnology, a subsidiary of the China-based company United Laboratories International Holdings, for UBT251. This potential anti-obesity medicine mimics the actions of three gut hormones: GLP-1, GIP, and glucagon. The transaction cost Novo Nordisk an up-front payment of $200 million and up to $1.8 billion in milestone payments. Thanks to all these developments, Novo Nordisk should remain a leader in weight management in the next decade. Even though competition is mounting, no drugmaker not named Eli Lilly has a lineup or a pipeline as deep as Novo Nordisk's. Furthermore, the Denmark-based pharmaceutical leader will also continue to dominate the diabetes market, as it has done for decades. Novo Nordisk generates consistent revenue and earnings that typically grow faster than those of similarly-sized peers. Yet the stock's forward P/E is 16.7, which is slightly above the industry average. In my view, that's a bargain for a company that generates better-than-average results and has a deep pipeline in a fast-growing area -- not to mention two of the world's top 20 best-selling drugs, in Wegovy and Ozempic. For investors willing to stay the course, Novo Nordisk's future still looks incredibly bright. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
14 hours ago
- Business Upturn
Sun Pharma reports positive results from Phase 3 trials for ILUMYA
Sun Pharmaceutical Industries has shared encouraging top-line results from two (Phase 3) clinical trials evaluating its biologic drug tildrakizumab 100 mg, marketed as ILUMYA®, for the treatment of active psoriatic arthritis (PsA). The studies, named INSPIRE-1 and INSPIRE-2, tested ILUMYA over a 24-week period. Patients who received ILUMYA showed significant improvements in symptoms of psoriatic arthritis compared to those who received a placebo. Both trials successfully met their primary goal—a higher proportion of patients treated with ILUMYA achieved ACR20 responses, a standard measure used to assess improvement in joint disease, by Week 24. The results were statistically significant. On the safety front, the drug performed as expected. There were no new safety concerns, and the data remained in line with ILUMYA's existing safety record. The drug is already approved to treat moderate-to-severe plaque psoriasis, and these latest findings suggest it may have potential in addressing PsA as well. However, it's important to note that ILUMYA is not yet approved for psoriatic arthritis, and its use for this indication has not been reviewed or authorized by health regulators. Marek Honczarenko, MD, PhD, Senior Vice President and Head of Global Specialty Development at Sun Pharma, stated, 'We are excited to share that both the INSPIRE-1 and INSPIRE-2 clinical trials have successfully met their primary endpoints. These top-line results reinforce the therapeutic potential of ILUMYA as a treatment option for patients with active psoriatic arthritis. We extend our sincere gratitude to the patients, healthcare professionals and administrators whose contributions made the studies possible. We look forward to sharing the complete clinical data in the near future.' Sun Pharma plans to present the full results from these studies at upcoming medical conferences and publish them in peer-reviewed journals. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
2 days ago
- Yahoo
2 Reliable Dividend Stocks With Yields Above 6% That You Can Buy With $100 Right Now
Key Points You don't need to be rich to get your money to start working for you. Healthpeak Properties and Pfizer offer dividend yields above 6% at recent prices. You can buy shares of Healthpeak Properties and Pfizer with well less than $100 at the moment. 10 stocks we like better than Healthpeak Properties › If putting your money to work on Wall Street is something you haven't started doing because it feels like a rich person's game and you're not one, I've got good news. Discount brokerages no longer charge the trading fees that made investing in small increments a losing proposition. These days, folks who invest in tiny increments are likely to receive identical returns to wealthier investors who make big trades. At the moment, anyone with $100 to spare can scoop up shares of Healthpeak Properties (NYSE: DOC) and Pfizer (NYSE: PFE). Both of these stocks offer dividend yields above 6% at recent prices. Plus, there are good reasons to expect payout raises from these stocks in the near term. Read on to see why they look like great options for everyday investors who want to grow their passive income stream. 1. Healthpeak Properties This healthcare-related real estate investment trust (REIT) expanded last year when Physicians Realty Trust and Healthpeak combined. Going into the merger, Healthpeak was focused on laboratories that are rented out to drugmakers of all sizes. Adding Physicians Realty Trust's portfolio of medical office buildings gave the REIT some diversification that investors appreciate. At the end of March, health systems and physician groups were responsible for 55% of annualized base rent. Drugmakers of different sizes were responsible for another 34% of annualized rent. Continuing care retirement communities and various other facilities rounded out the rest of the portfolio. At 10.1% of annualized rent, HCA Healthcare, a publicly traded hospital operator, is Healthpeak's biggest tenant. Its next largest tenant, CommonSpirit Health, is responsible for 2.9% of rental revenue. Investors can look forward to increasing dividend payouts from Healthpeak Properties stock in the near term. Management expects funds from operations (FFO), a proxy for earnings used to evaluate REITs, to land in a range between $1.81 and $1.87 per share this year. This is more than enough to support raising a payout currently set at an annualized $1.22 per share. The vast majority of Healthpeak's properties are rented out under net leases that leave tenants responsible for nearly all the variable costs associated with owning its buildings. With annual rent escalators written into long-term leases, investors can reasonably expect this REIT's dividend payout to move steadily in the right direction over the long run. 2. Pfizer Shares of America's largest drugmaker are down by about 60% from a peak they reached in 2021. The past four years have been disappointing from a principal-appreciation standpoint, but income-seeking investors are doing just fine. Pfizer's dividend payout has grown every year since 2009. At its beaten down price the stock offers an eye-popping 6.9% dividend yield as I write this. In addition to COVID-19-related revenue that collapsed faster than expected, Pfizer stock is way down because investors are worried about upcoming patent cliffs regarding top-selling medications. Investors have good reasons to be concerned about Pfizer's future cash flows. Earlier this year, CEO Albert Bourla warned that market exclusivity losses would likely reduce revenue by $17 billion to $18 billion beginning in 2026 and ending in 2028. With total sales that rose to $62.5 billion during the 12 months ended this March, filling the holes that exclusivity losses could punch in its income statement won't be easy. Luckily, the company reinvested much of its COVID-19 windfall into a productive development pipeline. In 2023, the Food and Drug Administration approved nine new medicines from Pfizer. In 2024, the company received over a dozen FDA approvals for both new and existing treatments. By 2030, management expects new products that Pfizer acquired to deliver $20 billion in annual revenue. That's enough to keep pushing its big needle forward despite expected losses to patent cliffs. Pfizer's $43 billion acquisition of Seagen in 2023 gave it access to several blockbuster cancer therapies. While their previous owner outsourced manufacturing, Pfizer's plan to bring manufacturing in-house could help profits expand faster than sales in the years ahead. I wouldn't expect rapid dividend payout raises from this stock in the years ahead, but steady movement in the right direction seems likely. Adding some shares to a diversified portfolio now looks like a smart move for investors who want big dividend payments that could grow even larger. Should you invest $1,000 in Healthpeak Properties right now? Before you buy stock in Healthpeak Properties, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Healthpeak Properties wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $687,149!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,060,406!* Now, it's worth noting Stock Advisor's total average return is 1,069% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends HCA Healthcare and Healthpeak Properties. The Motley Fool has a disclosure policy. 2 Reliable Dividend Stocks With Yields Above 6% That You Can Buy With $100 Right Now was originally published by The Motley Fool Sign in to access your portfolio
